Out-licensing: Technology For Treatment Of Melasma And Hyperpigmentation

Latest: Watch here for details of new products and services.

About Us: Innovaro Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Pay-per-Click New!; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Innovaro Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd

Out-licensing
View

Technology for treatment of Melasma and Hyperpigmentation

Clinically proven, commercial formulations for both prescription and over the counter sales.

Full description

HBS has both hydroquinone and hydroquinone free technologies for treatment of melasma and hyperpigmentation. All products are combined with retinol to provide enhanced performance with excellent tolerability through the encapsulation of the retinol in company's proprietary delivery systems.

The combination kojic acid/retinol formula was clinically proven to be statistically equivalent to 2% hydroquinone products.

Development status

Preregistration

Type of business relationship sought

Limited exclusivity available in selected countries.

Licensing contact

Mr Kevin Cureton
Managing Director
General Management

Contact directly

Company details

AMCOL Health & Beauty Solutions, Inc

AMCOL Health & Beauty Solutions, Inc develops and manufactures leading products for the dermatology field using its proprietary formulations and delivery systems; Microsponge and Poly-Pore.

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Optimags SPECIAL KNIFE COATER TECHNOLOGY

Using its proprietary NovaSperse℠ nanoparticle technology, PharmaNova seeks partners for the development of client-sponsored APIs and also for the partnered development of a series of new product opportunities in oncology, ophthalmology and dermatology.

Matriptase Hypomorphic Mouse Model of a Human Ichthyosis

An Improved Medical Laser for Dermal Applications: Personalized Interactive Laser Therapy (PILT) of Port-Wine Stain and other Surface Applications (09-14)

Related categories

Industry sector: Drug delivery / Topical / Dermatological; Drug delivery; Pharmaceutical / OTC/Non-Prescription; Pharmaceutical; Pharmaceutical / Prescription; Drug delivery / Topical
Therapeutic target: Dermatological; Dermatological / Dermatological (other); Dermatological / Skin infection (other)

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Innovaro Pharmalicensing current industry press releases.

Products:	Partnering Search	Pay-per-Click	Company Profiling	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us